Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment

Yan Chen, Ella X. Du (), Manasvi Sundar, Keith A. Betts, Xin Yin, Samantha Eiffert, Karen Beauchamp, Andrew Delgado and Lisa Rosenblatt
Additional contact information
Yan Chen: Analysis Group, Inc.
Ella X. Du: Analysis Group, Inc.
Manasvi Sundar: Analysis Group, Inc.
Keith A. Betts: Analysis Group, Inc.
Xin Yin: Bristol Myers Squibb
Samantha Eiffert: Bristol Myers Squibb
Karen Beauchamp: Bristol Myers Squibb
Andrew Delgado: Bristol Myers Squibb
Lisa Rosenblatt: Bristol Myers Squibb

PharmacoEconomics - Open, 2025, vol. 9, issue 1, No 12, 125-136

Abstract: Abstract Aim This study evaluated costs associated with adverse events (AEs) in previously untreated real-world patients with advanced renal cell carcinoma (aRCC) in the USA. Materials and Methods This retrospective longitudinal cohort study analyzed data from the Merative MarketScan Research Database (1 January 2014–30 September 2021). Adult patients with aRCC receiving first-line systemic treatments for aRCC (tyrosine kinase inhibitors [TKIs], or combination therapies of TKIs and immunotherapy) on or after the date of aRCC diagnosis were included. A total of 27 AEs of interest were included based on a review of product labels of the first-line treatments included in the study and identified using International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification codes. Incremental costs associated with AEs between cases and controls (unadjusted and adjusted for relevant baseline characteristics) were estimated by two-part modeling. Analyses were performed over three AE cost assessment periods (7, 14, and 30 days). Results The study included 1681 patients with aRCC (mean [standard deviation; SD] age, 60.8 [10.6] years; 73.1% male), of which 1542 (91.7%) had at least one AE. AEs were mostly diagnosed in the outpatient (OP) setting. For most AEs, cases had significantly higher unadjusted and adjusted costs than controls. Costs associated with AEs ranged from

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00534-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:1:d:10.1007_s41669-024-00534-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00534-2

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().